SODIUM BICARBONATE injection, solution

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

지금 구매하세요

Download 제품 특성 요약 (SPC)
29-02-2024

유효 성분:

SODIUM BICARBONATE (UNII: 8MDF5V39QO) (BICARBONATE ION - UNII:HN1ZRA3Q20, SODIUM CATION - UNII:LYR4M0NH37)

제공처:

Hospira, Inc.

관리 경로:

INTRAVENOUS

처방전 유형:

PRESCRIPTION DRUG

치료 징후:

Sodium Bicarbonate Injection, USP is indicated in the treatment of metabolic acidosis which may occur in severe renal disease, uncontrolled diabetes, circulatory insufficiency due to shock or severe dehydration, extracorporeal circulation of blood, cardiac arrest and severe primary lactic acidosis. Sodium bicarbonate is further indicated in the treatment of certain drug intoxications, including barbiturates (where dissociation of the barbiturate-protein complex is desired), in poisoning by salicylates or methyl alcohol and in hemolytic reactions requiring alkalinization of the urine to diminish nephrotoxicity of hemoglobin and its breakdown products. Sodium bicarbonate also is indicated in severe diarrhea which is often accompanied by a significant loss of bicarbonate. Treatment of metabolic acidosis should, if possible, be superimposed on measures designed to control the basic cause of the acidosis – e.g., insulin in uncomplicated diabetes, blood volume restoration in shock. But since an appreciable time interval may elapse before all of the ancillary effects are brought about, bicarbonate therapy is indicated to minimize risks inherent to the acidosis itself. Vigorous bicarbonate therapy is required in any form of metabolic acidosis where a rapid increase in plasma total CO2 content is crucial – e.g., cardiac arrest, circulatory insufficiency due to shock or severe dehydration, and in severe primary lactic acidosis or severe diabetic acidosis. Sodium Bicarbonate Injection, USP is contraindicated in patients who are losing chloride by vomiting or from continuous gastrointestinal suction, and in patients receiving diuretics known to produce a hypochloremic alkalosis.

제품 요약:

Sodium Bicarbonate Injection, USP is supplied in the following dosage forms. NDC Number (Unit of Sale) 0409-5555-02 NDC Number (Each) 0409-5555-12 Dosage Form Glass vial Conc. % 4.2 mg/mL (NaHCO3 ) 42 mEq/mL (Na+ ) 0.5 mEq/mL (HCO3 – ) 0.5 mEq/Container size (mL) 2.5/5 mOsm/mL 0.84 pH 8.0 (7.0 – 8.5) Store at 20 to 25°C (68 to 77°F). [See USP Controlled Room Temperature.] Protect from freezing. Hospira, Inc., Lake Forest, IL 60045 USA                                                                                  LAB-0809-2.0 Revised: 01/2018

승인 상태:

Abbreviated New Drug Application

제품 특성 요약

                                SODIUM BICARBONATE- SODIUM BICARBONATE INJECTION, SOLUTION
HOSPIRA, INC.
----------
4.2% SODIUM BICARBONATE
Injection, USP
FOR THE CORRECTION OF
METABOLIC ACIDOSIS AND
OTHER CONDITIONS REQUIRING
SYSTEMIC ALKALINIZATION.
Glass Vial
Rx
only
DESCRIPTION
Sodium Bicarbonate Injection, USP is a sterile, nonpyrogenic,
hypertonic solution of
sodium bicarbonate (NaHCO ) in water for injection for administration
by the
intravenous route as an electrolyte replenisher and systemic
alkalizer.
The solution is offered in a concentration of 4.2%. See table in HOW
SUPPLIED section
for contents and characteristics.
The solution has an approximate pH of 8.0 (7.0 – 8.5). It contains
no bacteriostat,
antimicrobial agent or added buffer and is intended only for use as a
single-use injection.
When smaller doses are required, the unused portion should be
discarded.
Sodium bicarbonate, 42 mg is equal to 0.5 milliequivalent each of Na
and HCO .
Sodium Bicarbonate, USP is chemically designated NaHCO , a white
crystalline powder
soluble in water.
Water for Injection, USP is chemically designated H O.
CLINICAL PHARMACOLOGY
Intravenous sodium bicarbonate therapy increases plasma bicarbonate,
buffers excess
hydrogen ion concentration, raises blood pH and reverses the clinical
manifestations of
acidosis.
Sodium bicarbonate in water dissociates to provide sodium (Na ) and
bicarbonate
(HCO ) ions. Sodium (Na ) is the principal cation of the extracellular
fluid and plays a
large part in the therapy of fluid and electrolyte disturbances.
Bicarbonate (HCO ) is a
normal constituent of body fluids and the normal plasma level ranges
from 24 to 31
mEq/liter. Plasma concentration is regulated by the kidney through
acidification of the
urine when there is a deficit or by alkalinization of the urine when
there is an excess.
Bicarbonate anion is considered "labile" since at a proper
concentration of hydrogen ion
3
+
3
-
3
2
+
3
-
+
3
-
+
(H ) it may be converted to carbonic acid (H CO ) and thence to its
volatile form,
carbon dioxide (CO ) excreted by the
                                
                                전체 문서 읽기
                                
                            

이 제품과 관련된 검색 알림